Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
October 25th, 2024
1.1K views
This protocol describes the procedure for performing in vivo PET imaging on mice using Body Conforming Animal Molds (BCAMs) in the G8 PET/CT scanner. Technical details on mouse preparation, including proper tumor implantation, optimal positioning, BCAM-assisted PET/CT image acquisition, and data analysis, are provided.
Overview
This protocol outlines the in vivo PET imaging process for mice using Body Conforming Animal Molds (BCAMs) in the G8 PET/CT scanner. It details mouse preparation, tumor implantation, image acquisition, and data analysis.
Key Study Components
Area of Science
- Neuroscience
- Imaging Techniques
- Pharmacology
Background
- In vivo imaging allows for holistic evaluation of drug distribution and effects.
- Standardization of animal positioning improves data reproducibility.
- Automated analysis tools can enhance efficiency in data processing.
- Challenges exist in manual segmentation of imaging data.
Purpose of Study
- To demonstrate the use of BCAMs for consistent mouse positioning during imaging.
- To evaluate the effectiveness of automated data analysis tools.
- To compare automated analysis results with manual methods.
Methods Used
- Preparation of mice with tumor cell injections.
- Use of BCAMs for imaging in the G8 PET/CT scanner.
- Data acquisition and analysis using cloud-based tools.
- Comparison of automated and manual segmentation results.
Main Results
- Automated analysis yielded results consistent with manual methods.
- High correlation observed in brain imaging between analysis methods.
- Moderate correlation for kidney and heart; challenges noted for spleen.
- Batch analysis significantly reduces processing time.
Conclusions
- BCAMs facilitate reproducible imaging in mice.
- Automated tools enhance efficiency and accuracy in data analysis.
- Further evaluation of automated methods is warranted.
Frequently Asked Questions
What are Body Conforming Animal Molds (BCAMs)?
BCAMs are molds designed to maintain consistent positioning of mice during imaging procedures.
How does in vivo imaging benefit drug development?
It allows for comprehensive evaluation of drug distribution and effects throughout the entire subject.
What is the significance of automated data analysis?
Automated analysis improves efficiency and reduces the potential for human error in data interpretation.
What imaging system is used in this protocol?
The G8 PET/CT scanner is utilized for imaging in this study.
How are tumor cells injected into the mice?
Tumor cells are injected subcutaneously using a needle guided by a temporary reference mark.
What parameters are important for PET imaging?
Mouse weight, date, time, dose amount, and injection details are critical parameters for accurate imaging.
Executive Industry Relevance
Automated PET imaging workflows using body-conforming animal molds and cloud-based segmentation address critical bottlenecks in preclinical biodistribution studies. This approach enhances reproducibility, reduces operator variability, and accelerates quantitative analysis, directly impacting early drug development decision points. Standardized, high-throughput imaging supports predictive confidence in compound distribution and target engagement assessments across the portfolio.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systemic, quantitative evaluation of compound biodistribution and pharmacological effects in vivo.
- Supports functional target validation by revealing both on-target and off-target tissue accumulation.
- Reduces mechanistic ambiguity through holistic, reproducible imaging data across timepoints.
- Facilitates predictive confidence in early-stage compound triage and prioritization.
Screening & Assay Development
- Prepares validated animal models for downstream imaging-based screening workflows.
- Standardizes animal positioning to minimize variability and improve assay reproducibility.
- Enables batch analysis and quantitative readouts for reliable compound evaluation.
- Supports scalable, automated workflows for high-throughput screening readiness.
Translational & Preclinical Research
- Aligns in vivo imaging outputs with translational biomarker strategies for preclinical validation.
- Provides continuity from discovery through preclinical assessment of tissue distribution and target engagement.
- Enables risk-adjusted advancement decisions based on robust, quantitative imaging data.
- Improves predictive de-risking by correlating in vivo imaging with ex vivo quantitation.
Pipeline & Workflow Integration
This workflow integrates from early discovery through lead identification and preclinical validation, supporting hypothesis testing and mechanistic de-risking at each stage.
- Discovery Biology: Facilitates hypothesis-driven evaluation of compound distribution and target engagement in vivo.
- Screening: Delivers standardized, reproducible imaging assays with quantitative outputs for compound comparison.
- Analytics: Provides automated, cloud-based segmentation and statistical analysis for robust data interpretation.
- Translational Research: Bridges discovery and preclinical phases by aligning imaging data with translational endpoints.
- Enterprise Reuse: Establishes a scalable, reusable imaging and analysis platform for diverse compound classes and biomarkers.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces biological risk through standardized, quantitative imaging.
- Operational Value: Streamlines workflows with automation, batch analysis, and reduced operator dependency.
- Strategic Value: Enables faster, data-driven go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of candidates based on robust biodistribution data.
Implementation Considerations
- Requires expertise in in vivo imaging and animal handling for consistent model preparation.
- Needs access to PET/CT instrumentation and cloud-based analytical infrastructure.
- Demands cross-team standardization of animal positioning and data annotation protocols.
- Adaptable to various biomarkers and radiolabeled compounds with minimal workflow changes.
- Dependent on the accuracy of automated segmentation, especially for anatomically challenging organs.
Biopharma FAQs
Why does null hypothesis testing matter for PET-based biodistribution analysis?
Null hypothesis testing in PET biodistribution studies enables objective assessment of whether observed compound distribution differs significantly from baseline or control, supporting robust target validation and mechanistic de-risking in early discovery.
How does independent variable isolation improve automated organ segmentation in PET imaging?
Isolating variables such as animal positioning with BCAMs ensures that differences in PET signal reflect true biological effects rather than technical variability, enhancing the reliability of automated segmentation outputs for downstream analysis.
What do quantitative dependent variable measurements enable in cloud-based PET analysis?
Quantitative measurements of tracer uptake across organs provide actionable data for comparing compound kinetics, tissue accumulation, and target engagement, enabling data-driven decisions in compound triage and advancement.
Why are replication requirements critical for cross-functional PET imaging studies?
Replication ensures that imaging results are reproducible across operators and timepoints, supporting cross-functional collaboration and confidence in data used for portfolio progression and regulatory submissions.
What statistical analysis capabilities are required before implementing automated PET quantitation?
Robust statistical tools are needed to compare automated and manual segmentation outputs, assess correlation across organs, and validate that automated quantitation meets accuracy thresholds for preclinical decision-making.
Chapters in this video
0:00
Introduction
2:08
Subcutaneous Tumor Cell Inoculation and Intravenous [18F]FDG Dose Administration in Mice for Positron Emission Tomography (PET) Imaging
4:09
Positioning of Mice in Body Conforming Animal Mold (BCAM) for PET Imaging
5:06
In Vivo PET Imaging and Data Analysis in Mice After Intravenous Administration of [18F]FDG
![Visualization and Quantification of Brown and Beige Adipose Tissues in Mice using [18F]FDG Micro-PET/MR Imaging](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62460.jpg%3Fv%3D2026-08-11T08%253A27%253A22.161Z&w=384&q=75)
